Novo Nordisk and Lilly are cutting prices on weight loss drugs like Ozempic, Wegovy, and Zepbound due to competition and agreements. Discounts now available for cash buyers and some Medicare/Medicaid recipients.
Novo Nordisk is reducing prices for Ozempic and Wegovy, offering a $199/month introductory price and lowering the 'typical' cost to $349/month. This makes them competitive with Lilly's Zepbound.
A new study reveals rising GLP-1 drug use in the US, especially among diabetics (45%). Cost remains a major concern, with many struggling to afford these medications despite insurance coverage. Medicare changes are coming.
The millennial-skewed tele-health platform Hims & Hers announced in May that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy.
